These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21807080)

  • 1. An effective novel delivery strategy of rasagiline for Parkinson's disease.
    Fernández M; Negro S; Slowing K; Fernández-Carballido A; Barcia E
    Int J Pharm; 2011 Oct; 419(1-2):271-80. PubMed ID: 21807080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
    Fernández M; Barcia E; Fernández-Carballido A; Garcia L; Slowing K; Negro S
    Int J Pharm; 2012 Nov; 438(1-2):266-78. PubMed ID: 22985602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism.
    Negro S; Boeva L; Slowing K; Fernandez-Carballido A; Garcia-García L; Barcia E
    Curr Pharm Des; 2017; 23(23):3423-3431. PubMed ID: 27779080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease.
    Kanwar N; Bhandari R; Kuhad A; Sinha VR
    Drug Deliv Transl Res; 2019 Oct; 9(5):891-905. PubMed ID: 30877626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease.
    Huang J; Liu H; Gu W; Yan Z; Xu Z; Yang Y; Zhu X; Li Y
    Biomaterials; 2006 Feb; 27(6):937-46. PubMed ID: 16118017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
    Normando EM; Davis BM; De Groef L; Nizari S; Turner LA; Ravindran N; Pahlitzsch M; Brenton J; Malaguarnera G; Guo L; Somavarapu S; Cordeiro MF
    Acta Neuropathol Commun; 2016 Aug; 4(1):86. PubMed ID: 27535749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.
    Jiang Y; Zhang X; Mu H; Hua H; Duan D; Yan X; Wang Y; Meng Q; Lu X; Wang A; Liu W; Li Y; Sun K
    Drug Deliv; 2018 Nov; 25(1):143-152. PubMed ID: 29275639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of roscovitine against rotenone-induced parkinsonism.
    Chen Y; Hou Y; Ge R; Han J; Xu J; Chen J; Wang H
    Restor Neurol Neurosci; 2018; 36(5):629-638. PubMed ID: 30056439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D₁ and D₂ receptor subtypes functional regulation in cerebral cortex of unilateral rotenone lesioned Parkinson's rat model: Effect of serotonin, dopamine and norepinephrine.
    Paul J; Kuruvilla KP; Mathew J; Kumar P; Paulose CS
    Parkinsonism Relat Disord; 2011 May; 17(4):255-9. PubMed ID: 21306935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
    Yang Y; Liu X; Long Y; Wang F; Ding JH; Liu SY; Sun YH; Yao HH; Wang H; Wu J; Hu G
    Int J Neuropsychopharmacol; 2006 Feb; 9(1):51-61. PubMed ID: 15927086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
    Abdin AA; Hamouda HE
    Neuropharmacology; 2008 Dec; 55(8):1340-6. PubMed ID: 18817789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism.
    Bali NR; Salve PS
    Int J Biol Macromol; 2020 Dec; 164():1006-1024. PubMed ID: 32619667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.
    D'Aurizio E; Sozio P; Cerasa LS; Vacca M; Brunetti L; Orlando G; Chiavaroli A; Kok RJ; Hennink WE; Di Stefano A
    Mol Pharm; 2011 Dec; 8(6):2408-15. PubMed ID: 22014118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
    Ho SC; Hsu CC; Pawlak CR; Tikhonova MA; Lai TJ; Amstislavskaya TG; Ho YJ
    Behav Brain Res; 2014 Jul; 268():177-84. PubMed ID: 24755306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
    Ren T; Yang X; Wu N; Cai Y; Liu Z; Yuan W
    Neurosci Lett; 2011 Sep; 502(2):117-22. PubMed ID: 21835223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D₁ and D₂ receptor subtypes functional regulation in corpus striatum of unilateral rotenone lesioned Parkinson's rat model: effect of serotonin, dopamine and norepinephrine.
    Paul J; Nandhu MS; Kuruvilla KP; Paulose CS
    Neurol Res; 2010 Nov; 32(9):918-24. PubMed ID: 20887679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
    Alam M; Danysz W; Schmidt WJ; Dekundy A
    Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
    Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
    Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.